ERBB2 and breast carcinoma: ERBB2/HER2 amplification is a marker of aggressive disease, although the development of the trastuzumab monoclonal antibody targeting the ERBB2/HER2 receptor has revolutionised breast cancer treatment regimes, leading to improved survival rates [21].